SKYRIZI is available as
a single 150 mg injection1

SKYRIZI is the only 4-dose-a-year biologic for Ps and for PsA
that offers a single-dose pen1


SKYRIZI is also available in a single-dose 150 mg/mL prefilled syringe.1

Discover the 150 mg/mL SKYRIZI PEN1-3

What stays the same with the SKYRIZI Pen1,2

Same SKYRIZI you
know and trust,
in a single
150 mg/mL injection*

Consistent efficacy
and safety profile

In-office or at-home
administration after
proper training

*Bioequivalence was demonstrated between a single 150 mg/mL injection and two 75 mg/0.83 mL injections in a prefilled syringe.
Bioequivalence was also demonstrated between 150 mg/mL prefilled syringe and prefilled pen.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after
training in subcutaneous injection technique.1

150 mg/mL SKYRIZI pen.

THE RESULTS ARE IN

In a questionnaire from a single-arm, open-label study, patients reported a
positive injection experience3,4

AT WEEK 28

98% (n=81/83) OF PATIENTS REPORTED

EASE OF USE

SKYRIZI Pen was
easy/very easy to use

CONVENIENCE

SKYRIZI Pen was
convenient/very convenient

SATISFACTION

They were satisfied/very
satisfied self-injecting
with the SKYRIZI Pen

DESCRIPTION: In an open-label, single-arm, multicenter study evaluating the SKYRIZI Pen (N=108), patient experience was reported through questions within 6 domains of a validated Self-Injection Assessment Questionnaire (SIAQ). Graphic includes percent of patients reporting easy/very easy, convenient/very convenient, satisfied/very satisfied for 3 questions within the ease of use and satisfaction domains at Week 28 (N=83).3,4

ADMINISTRATION INSTRUCTIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the

.1